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httpcense.Abstract Objective: Malignant pleural effusions (MPE) are characterized by rapid reaccumula-
tion, after tapping, and many symptoms related. Pleurodesis, for the management of MPE, is
intended to achieve symphysis between parietal and visceral pleura, and to prevent relapse of pleu-
ral effusion. Many chemical agents are tried to induce abrasion and damage of the pleural mesothe-
lial layer to achieve this symphysis.
Aim: The aim of this study is to compare the results of medical pleurodesis, using 4 different
chemical agents in these cases, to reach an efﬁcient one with minimal complications.
Methods: Between July 2010 and July 2012, 40 patients with MPE, divided into 4 groups, under-
went medical pleurodesis using 4 chemical agents in comparison: bleomycin, doxycycline, povidone
iodine and 5-ﬂuorouracil.
Results: Immediately and for 3 months after the procedure, the results of pleurodesis were
assessed and the ﬁnal reported success rates were 70% for bleomycin, 80% for doxycycline and
80% for povidone iodine, while 5 ﬂuorouracil had the lowest success rate (50%) (P-value < 0.05).
Conclusion: Bleomycin, doxycycline and povidone iodine are nearly equally effective and safe
pleurodetic agents when used in the optimal dose, while 5-ﬂuorouracil had a much higher failure
rate. Although povidone iodine and doxycycline are as effective and safe as bleomycin, they are
cheaper alternatives and more available chemical agents for pleurodesis in cases with MPE.
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Malignant pleural effusions (MPE), which comprise a hetero-
geneous group of conditions, represent an important source of
morbidity for patients with underlying cancer [1].
The standard management approach begins with a diag-
nostic and/or therapeutic thoracentesis. If the effusion recurs,
other options include repeated thoracentesis, tube thoracos-is. Production and hosting by Elsevier B.V.
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400 R.M. Bakr et al.tomy with chemical pleurodesis, placement of an indwelling
cuffed, tunneled pleural catheter with or without pleurodesis,
medical thoracoscopy or video-assisted thoracoscopic surgery
with pleurodesis [2].
Pleurodesis is the obliteration of the pleural space by fusion
of the visceral and parietal pleurae with ﬁbrous tissue in recur-
rent and symptomatic pleural effusions and pneumothoraces.
Most of the agents used for pleurodesis injure the pleura and
cause an inﬂammatory reaction together with a pleural effu-
sion. Subsequently, the local activation of the coagulation sys-
tem and the production of ﬁbrogenic cytokines such as
transforming growth factor b lead to the production of colla-
gen that can result in a pleurodesis [3].
It has been supposed that the ideal pleural sclerosing agent
should be easily administered, safe, inexpensive, and widely
available [4]. None of the agents presently used meet all of
these criteria, and the search is still on. Huge varieties of scle-
rotic agents have been tested, with various success rates and
drawbacks. They include talc, antibiotics (tetracyclines, mino-
cycline, doxycycline), antimalarials (quinacrine, mepacrine),
antineoplastic drugs (bleomycin, 5-ﬂuorouracil, mitomicin,
thiotepa, nitrogen mustard), 50% glucose and water, immuno-
modulating agents [interferon (IFN)-a, IFN-c], iodopovidone,
radioactive colloidal gold, autologous blood, ﬁbrin glue, bio-
logical agents (suspension of killed Corynebacterium parvum,
or bacille Calmette–Gue´rin), and ﬁnally nitrates [3,4].
Aim
The aim of this study is to compare the results of medical pleu-
rodesis, using 4 different chemical agents; bleomycin am-
poules, doxycycline capsules, povidone iodine solution and 5-
ﬂuorouracil ampoules, in cases of MPE, as regards; efﬁcacy,
safety, availability and cost.Patients and methods
This study was carried out on 40 patients with MPE (23
patients had right and 17 patients had left pleural effusions),
consisted of 4 females and 36 males, with age ranging from
45 to 76 years, admitted in, and referred to, the Chest Depart-
ment, Menouﬁya University during the period from July 2010
to July 2012. Regarding the aetiology of MPE, 14 cases were
due to mesothelioma, 10 cases were due to metastasic
adenocarcinoma of unknown origin and 16 cases were due to
metastasis from different known origins: [lymphoma (3 cases),
squamous cell lung carcinoma (3 cases), small cell lung
carcinoma (2 cases), breast carcinoma (3 cases), hepatocelluler
carcinoma (2 cases), abdominal sarcoma (one case), cancer-
cervix (one case), and transitional cell carcinoma of bladder
(one case)].
They were evaluated by detailed medical history, clinical
examination, laboratory and radiological investigations
(including CT chest), thoracentesis and pleural ﬂuid analysis
and closed pleural biopsy, using Abrams needle. All patients
included in this were having free MPE, clinically and on CT
examination, and those with probable adhesions were
excluded. They were subjected to pleurodesis through an
intercostal tube 28–36 French gauge, inserted under local
anesthesia in the 5th intercostal space in the mid-axillary line.They were randomized into four equal groups, each group
consisted of 10 patients. The patients of the ﬁrst group
(Group-I) were subjected to pleurodesis with 60 mg bleomycin
sulfate (bleocine Nippon-kayaky Company, 4 vials 15 mg/
vial, cost 125 EP/vial with total cost of 500 EP), were used
for each patient, diluted in 50 ml of saline 0.9% and 10 ml of
2% xylocaine solution [5]. Seven milligram per kilogram of
doxycycline (vibramycin, Pﬁzer Company, 100 mg capsules,
costing 20 EP for the pack and the total cost for the patient),
diluted in 50 ml of saline 0.9% and 10 ml of 2% xylocaine
solution were used for pleurodesis in each patient in the second
group (Group-II) [6].
Twenty milliliter of 10% povidone iodine (betadine, Mundi-
pharma AG Company, 200 ml bottle of 10.5 EP cost for each
patient), diluted in 50 ml of saline 0.9% and 10 ml of 2% xylo-
caine were used for pleurodesis in the third group (Group-III)
[7]. Patients in the fourth group (Group-IV) were subjected to
pleurodesis with 5 ﬂuorouracil(ﬂoracil, Cipla Company, vials
500 mg/5 ml, 10 EP for the vial with a total cost of 40 EP for
the patient), administered intra-pleurally in doses of 2 g diluted
in 50 ml of saline 0.9% plus 10 ml of 2% xylocaine [8]. After
intrapleural injection of the pleurodetic agent, the tube was
clamped and the patient was rotated for 1 h, to guarantee ade-
quate pleural distribution. After 1 h, the tube was opened for
up to 72 h drainage, without negative suction application,
and when the ﬂuid drained was less than 250 ml/24 h, the tube
was removed. All patients were followed up through the days
of hospital stay, till discharge and for 3 months after pleurod-
esis, with clinical and radiological chest assessment.
The response to pleurodesis was considered to be;
* Complete response (CR): if there was no reaccumulation
of pleural ﬂuid in the same hemithorax, after tube
removal, during the 1st week of the procedure and all
through the follow up period.
* Partial response (PR): if there was accumulation of some
ﬂuid, early after tube removal (1–7 days), not causing
symptoms and not requiring repeated thoracocentesis or
tube drainage.
* Failure of pleurodesis: was considered if there was difﬁ-
culty to remove the tube, because the pleural ﬂuid drained
through it is more than 250 ml/24 h (primary failure) or
there was ﬂuid reaccumulation after tube removal, that
caused symptoms to the patient or necessitated repeated
thoracocentesis or intercostal tube drainage, during the
follow up period (secondary failure).
Results
Tables 1 and 2 show that the age of the patients in the ﬁrst
group ranged from 45 to 73 years, with a mean value of
60.7 ± 8.7 years; 9 males and one female. In the second
group; the age ranged from 49 to 76 years with a mean
62.5 ± 8.6 years; 8 males and 2 females. In the third group;
the age ranged from 46 to 71 years with a mean
64.3 ± 7.6 years; all the 10 patients in this group were males.
Lastly, in the fourth group; the age ranged from 50 to
74 years with a mean value of 64.5 ± 7.7 years; 9 males
and one female. There were insigniﬁcant differences between
Table 1 Age distribution among the studied groups.
Group N Range Mean SD F P-value Sig.
Min. Max.
I Bleomycin 10 45 73 60.7 8.7 0.47 0.70 NS
II Doxycycline 10 49 76 62.5 8.6
III Povidone-iodine 10 46 71 64.3 7.6
VI Fluorouracil 10 50 74 64.5 7.7
Table 2 Sex distribution among the studied groups.
Group I Bleomycin II Doxycycline III Povidone-iodine VI Fluorouracil P-value
Gender N= 10 N= 10 N= 10 N= 10
No % No % No % No %
Male 9 90.0 8 80.0 10 100.0 9 90.0 0.53
Female 1 10.0 2 20.0 0 0.0 1 10.0 NS
Table 3 Comparison between different studied groups as regards the duration of hospital stay after pleurodesis.
Group I Bleomycin II Doxycycline III Povidone-iodine VI 5 Fluorouracil One way anova P-value
Tube duration N= 10 N= 10 N= 10 N= 10
X± SD Day 4.6 ± 1.2 3.8 ± 1.1 4.3 ± 1.1 7.1 ± 2.5 2.85 0.02 S
Table 4 The immediate follow up results of pleurodesis for the studied groups.
Group I Bleomycin II Doxycycline III Povidone-iodine IV Fluorouracil P-value
Response to pleurodesis N= 10 N= 10 N= 10 N= 10
No % No % No % No %
Complete response 6 60 8 80.0 7 70.0 4 40.0 0.04 S
Partial response 2 20.0 1 10.0 1 10.0 1 10.0
Failure 2 20.0 1 10.0 2 20.0 5 50.0
Table 5 The follow up results of pleurodesis after 8 weeks for the studied groups.
Group I Bleomycin II Doxycycline III Povidone-iodine VI Fluorouracil P-value
Response N= 10 N= 10 N= 10 N= 10
No % No % No % No %
Complete recovery 7 70.0 8 80.0 8 80.0 5 50.0 0.02 S
Failure 3 30.0 2 20.0 2 20.0 5 50.0
Pleurodesis using different agents in malignant pleural effusion 401the patients of the different studied groups as regards age or
sex (P-value > 0.5).
Table 3 shows the mean duration of hospital stay after
pleurodesis and it was 4.6 ± 1.2, 3.8 ± 1.1, 4.3 ± 1.1 and
7.1 ± 2.5 days for groups I, II, III and IV respectively and
the duration in the 5 ﬂuorouracil group (4th group) was sig-
niﬁcantly longer than the other three groups (P
value < 0.05).Table 4 shows the immediate follow up results (24–72 h of
pleurodesis) in the 4 different studied groups and there was a
recorded complete response in 60%, 80% and 70% of patients
in groups I, II and III respectively, while it was only 40% in
group IV (5-ﬂuorouracil group), which is signiﬁcantly lower
than those of the other three groups (P value < 0.05).
Tables 5 and 6 show that the follow up results of pleurod-
esis in the 4 different studied groups after 2 and 3 months of
Table 6 The ﬁnal follow up results after 12 weeks of pleurodesis in the 4 different studied groups.
Group I Bleomycin II Doxycycline III Povidone-iodine VI Fluorouracil P-value
Response N= 10 N= 10 N= 10 N= 10
No % No % No % No %
Complete recovery 7 70.0 8 80.0 8 80.0 5 50.0 0.02 S
Failure 3 30.0 2 20.0 2 20.0 5 50.0
Table 7 The complications of pleurodesis in the 4 studied groups.
Group I Bleomycin II Doxycycline III Povidone-iodine VI Fluorouracil P-value
Complication N= 10 N= 10 N= 10 N= 10
No % No % No % No %
Empyema 1 20.0 1 10.0 0 0.0 2 20.0 0.78 NS
Fever 3 30.0 3 30.0 5 50.0 4 40.0
Pain 6 60.0 6 60.0 5 50.0 4 40.0
Table 8 Spearman’s correlation between ﬁnal follow up
results and age, pH, glucose levels and type of malignancy.
Variable Follow up results
Correlation
coeﬃcient (r)
Age 0.041 0.799 NS
pH 0.717 0.001 HS
Glucose 0.708 0.001 HS
Malignancy type 0.031 0.848 NS
402 R.M. Bakr et al.the procedure were the same and the ﬁnal success rate for; ble-
omycin pleurodesis was 70%, doxycycline was 80%, povidone
iodine was 80% (the difference between these three groups is
insigniﬁcant), and the ﬁnal success rate for group IV (5-ﬂuoro-
uracil group) was 50%, which is signiﬁcantly lower than that
for the other groups (P value < 0.05).
Table 7 shows that in the ﬁrst two groups, 50% of patients
had chest pain, 30% had fever and 20% had empyema, in
group III, 50% of patients developed chest pain and 50%
had fever. In group IV, 40% of patients developed chest pain,
40% had fever and 20% had empyema. There was no statisti-
cally signiﬁcant difference (P-value > 0.5) between all groups
as regards the complications.
This table shows a positive correlation between the pleural
ﬂuid pH and glucose levels and the success of pleurodesis, but
not with the age of the patient or the type of malignancy. (See
Table 8)
Discussion
The mean age of the patients included in our study was
60 ± 15 years.
Thirty six patients were males and 4 were females. The 4
groups were comparable as regards the age and sex. 23 patients
had right effusion and 17 had left effusion. The malignant
pleural effusions were either of primary pleural origins (malig-
nant mesothelioma) in 14 patients or of metastatic etiology in26 patients. Ten cases were due to metastatic adenocarcinoma
of unknown origin and 16 cases were due to metastasis from
different origins.
As regards the mean durations of hospital stay for
pleurodesis, they were 4.6 ± 1.2, 3.8 ± 1.1, 4.3 ± 1.1 and
7.1 ± 2.5 days for groups I, II, III and IV respectively. The
duration of hospital stay in the 5 ﬂuorouracil group (the 4th
group) was signiﬁcantly longer than the other three groups
(P value < 0.05) and this was related to either the occurrence
of complications or failure of pleurodesis and need for another
intervention (Table 3).
In this study, the immediate follow up results showed that
in group I, complete response (CR) was recorded in 6 cases
(60%), while partial response (PR) was found in 2 cases
(20%) and failure was found in 2 cases (20%) with an early
success rate of 60%. In group II, 8 patients had CR (80%)
while partial response (PR) was recorded in 1 case (10%)
and failure in 1 case (10%), with a success rate of 80%. In
group III, 7 patients had CR (70%), while partial response
(PR) was found in 1 case (10%) and failure was found in 2
cases (20%) with a success rate of 70%. In group IV, 4 patients
had CR (40%), 1 had PR (10%) and failure was recorded in 5
cases (50%) with an early success rate of only 50%, which was
signiﬁcantly lower (P value < 0.05) than that of the previous 3
groups (Table 4).
After two and three months follow up of the patients in all
groups, patients in group I showed complete response (CR) in
7 cases (70%), while failure was found in 3 cases (30%) with a
success rate of 60%, in group II, 8 patients had CR (80%),
while failure was found in 2 cases (20%) with a success rate
of 80% and in group III, 8 patients had CR (80%) and failure
was found in 2 cases (20%) with a success rate of 80% and the
difference between these three groups was statistically insignif-
icant (P-value > 0.5). In group IV, 5 patients had CR (50%),
while failure was recorded in 5 cases (50%) with a success rate
of only 50%, which was signiﬁcantly lower than the previous 3
groups (P value < 0.05) (Tables 4 and 5).
Edward and coworkers [9] carried out a prospective ran-
domized trial on bleomycin versus doxycycline with small-bore
Pleurodesis using different agents in malignant pleural effusion 403catheter drainage, there was no signiﬁcant difference in 30-
days response rates between both drugs. Our results were high-
er than those of a study done by Kessinger and Wigton [10] on
13 patients who were given bleomycin pleurodesis for MPE
and the reported success rate was 62%.
However, our results of bleomycin pleurodesis (70% suc-
cess rate) were lower than, yet comparable to, that achieved
by Emad and Rezaian [11], who reported a success rate of
89.4% in 20 patients receiving bleomycin via chest tube.
The current study results on doxycycline pleurodesis agree
with those of a study done by Herrington [12], who evaluated
doxycycline as a pleurodetic agent in treatment of malignant
and nonmalignant pleural effusions and refractory pneumo-
thoraces, in 27 consecutive patients requiring pleurodesis. 23
of 27 patients were evaluated at 30 days. 6 patients (67%)
out of 9 patients with pneumothoraces achieved a response,
and 2 patients with nonmalignant pleural effusions had a com-
plete response. Out of 12 patients with malignant pleural effu-
sion, 8(67%) achieved a complete response, 2 had a partial
response, and 2 had no response. In this limited number of pa-
tients, doxycycline pleurodesis with 1 g appeared to be a very
available, cheap, safe and effective drug for the treatment of
pleural effusions and pneumothoraces.
Also we agree with Maj and colleagues [13], who compared
pleurodesis with erythromycin, talc, doxycycline, and diaze-
pam in a rabbit model, this study demonstrated that erythro-
mycin may be an ideal sclerosing agent. It had the advantage
of maximal ﬁbrosis with minimal inﬂammation. Although
doxycycline was the most potent pleural sclerosant, it caused
severe local tissue damage. Talc pleurodesis resulted in only
mild pleural ﬁbrosis and diazepam was ineffective.
Also, Elnady and Sakr [14] studied the safety and efﬁcacy
of pleurodesis with thoracoscopic doxycycline poudorage in
malignant pleural effusion and the results showed that
74.1% of patients had successful pleurodesis, 18.5% had par-
tial response and 7.4% had failed pleurodesis at one month
follow up. They concluded that doxycycline is an inexpensive,
well tolerated, reasonably effective, comparatively simple, safe,
and capable of alleviating respiratory symptoms. However,
these results were lower than that achieved by our study and
this may be due to the different methodology.
This study showed povidone-iodine as an effective (CR
80%), safe, very cheap and easily available agent for pleurod-
esis. This agree with Carlos and colleagues [15], who studied
iodopovidone pleurodesis in recurrent pleural effusions and
found that iodopovidone is an effective, safe, readily available,
and inexpensive alternative to achieve chemical pleurodesis in
cases of recurrent, incapacitating effusions, regardless the
etiology.
Many researchers reported similar results for this drug as
pleurodetic agent. In 2004, a meta-analysis of observational
studies on the efﬁcacy and safety of iodopovidone use in chem-
ical pleurodesis, was done by Shaw and Agarwal [2] and re-
vealed that the success rate of pleurodesis ranged from
64.2% to 100%, with overall success rate of 90.6% in all the
studies.
However, our study showed a lower success rate for 5 ﬂuo-
rouracil (50%) in pleurodesis than that mentioned by Harry
and colleagues [16] in a prospective non randomized study
on 21 patients with malignant pleural effusion. They found
no symptomatic effusion recurred and no substantial side ef-
fects were associated with treatment and suggested that 5-ﬂuo-rouracil represents a safe and effective intrapleural agent for
pleurodesis.
In another study on patients with recurrent, symptomatic,
malignant pleural effusions treated with 5-ﬂuorouracil, Pamela
and coworkers [3], reported a success rate of 66% for 5-ﬂuoro-
uracil as a pleurodetic agent, with no reports for pain, fever or
emesis, which were higher than our results. This may be ex-
plained by the small sample size of our study.
There was a positive correlation between the success of
pleurodesis on one side and the pleural ﬂuid pH and glucose
levels on the other side. This can be explained by the abnormal
pleural membrane that results from tumor inﬁltration and the
high tumor burden that appears primarily responsible for the
low pH and glucose level in the malignant pleural ﬂuid. There
is impaired glucose transfer from blood to pleural ﬂuid and
vice versa in these patients with low ﬂuid pH but not in
normal-pH malignant effusions. Glucose in pleural ﬂuid is
metabolized into the end products CO2 and lactic acid. Due
to abnormal pleura in patients with low pH effusions, the rate
of transport of CO2 and lactic acid out of pleural space is
slowed and accumulation occurs resulting in decreased
pleural ﬂuid pH [17]. Crnjac and sok [18], studied the impact
of pleural effusion pH on the efﬁcacy of thoracoscopic
mechanical pleurodesis in patients with breast carcinoma,the
result was that at low pH values the success of pleurodesis is
reduced.
In his study, Shoukry [19] showed similar results. He
reported that pleural ﬂuid levels of pH and LDH were the
most sensitive markers that discriminated those with failed
pleurodesis from those with successful pleurodesis, where the
cut-off points that discriminated success from failure were
pH < 7.33 and LDH> 1023 IU/l and with decreasing
pH < 7.33 and increasing LDH> 1023 IU/l, there was
increased probabilities of pleurodesis failure.
Complications of pleurodesis were recorded immediately
after the procedure till discharge of the patients. In group I,
6 patients had chest pain, 3 patients had fever and one had
empyema. The same results were found in group II. In group
III, 5 patients developed chest pain and 5 had fever. In group
IV, 4 patient developed chest pain, 4 had fever and 2 had
empyema. There was no statistically signiﬁcant difference be-
tween the groups as regards the complications (Table 4).
Our study had the same results as Herrington [12] where
twenty-two (81%) of 27 patients in his study experienced ad-
verse effects with pleurodesis, with pain (81%) and fever
(11%) being the most prevalent. As pain is the most common
complication associated with doxycycline pleurodesis, narcotic
analgesic and/or conscious sedation is often recommended or
the solution may be mixed with 10 ml of lignocaine to reduce
pain. A meta-analysis of observational studies made by
Agarwal [20], the only signiﬁcant complication of iodopovi-
done reported was chest pain of varying degrees. Systemic
hypotension was reported in three patients in only one study.
There were no deaths related to chemical pleurodesis with
iodopovidone.
On the other hand, Aelony [21] reported severe hypotension
and pain due to iodopovidone occurred in 3 of the 5 patients
with mesothelioma, in his study which included 52 patients,
after iodopovidone pleurodesis. He suggested that this may
be a unique complication in mesothelioma patients, and thus
he does not justify injecting iodopovidone either via chest tube
or via thoracoscope, except with some precautions.
404 R.M. Bakr et al.Conclusion
From this study we can conclude that doxycycline capsules
and povidone iodine solution are effective, cheap and very
available pleurodetic agents with fewer complications and their
results are comparable to those obtained for bleomycin in
pleurodesis, which is more expensive, less available and may
be, as a cytotoxic drug, with more side effects.References
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